CA2510043A1 - Formulations de solutions aux hfc contenant du tiotropium - Google Patents
Formulations de solutions aux hfc contenant du tiotropium Download PDFInfo
- Publication number
- CA2510043A1 CA2510043A1 CA002510043A CA2510043A CA2510043A1 CA 2510043 A1 CA2510043 A1 CA 2510043A1 CA 002510043 A CA002510043 A CA 002510043A CA 2510043 A CA2510043 A CA 2510043A CA 2510043 A1 CA2510043 A1 CA 2510043A1
- Authority
- CA
- Canada
- Prior art keywords
- acid
- hfc
- solution formulation
- aerosol solution
- formulation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention a trait à des formulations de solutions pharmaceutiques stables contenant du tiotropium et pouvant être administrées en aérosol. Plus précisément, la présente invention concerne une formulation de solution pharmaceutique stable contenant du tiotropium et pouvant être administrée en aérosol, dans laquelle un acide soit minéral soit organique est ajouté à la formulation de solution pour aérosol, qui contient un sel de tiotropium, de préférence du bromure de tiotropium en solution, un hydrofluorocarbone (HFC) servant de propulseur, et un composé organique faisant fonction de cosolvant. L'acide procure au médicament une stabilité lui permettant de résister à la dégradation ou la décomposition, lesquelles sont causées principalement par l'interaction du médicament avec le cosolvant et/ou l'eau présents dans la formulation de solution.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02028238 | 2002-12-16 | ||
EP02028238.0 | 2002-12-16 | ||
PCT/EP2003/013692 WO2004054580A1 (fr) | 2002-12-16 | 2003-12-04 | Formulations de solutions aux hfc contenant du tiotropium |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2510043A1 true CA2510043A1 (fr) | 2004-07-01 |
Family
ID=32524008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002510043A Abandoned CA2510043A1 (fr) | 2002-12-16 | 2003-12-04 | Formulations de solutions aux hfc contenant du tiotropium |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1575588A1 (fr) |
JP (1) | JP2006510680A (fr) |
KR (1) | KR20050085650A (fr) |
CN (1) | CN1726038A (fr) |
AU (1) | AU2003303029A1 (fr) |
BR (1) | BR0317340A (fr) |
CA (1) | CA2510043A1 (fr) |
IL (1) | IL169178A0 (fr) |
MX (1) | MXPA05006383A (fr) |
PL (1) | PL375868A1 (fr) |
RU (1) | RU2005122444A (fr) |
WO (1) | WO2004054580A1 (fr) |
ZA (1) | ZA200503546B (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7273603B2 (en) * | 2003-07-11 | 2007-09-25 | Boehringer Ingelheim International Gmbh | HFC solution formulations containing an anticholinergic |
CN101203513A (zh) * | 2005-05-02 | 2008-06-18 | 贝林格尔·英格海姆国际有限公司 | 噻托溴铵的晶型 |
ES2393794T3 (es) * | 2005-05-02 | 2012-12-28 | Boehringer Ingelheim International Gmbh | Nuevas formas cristalinas de bromuro de tiotropio |
US9108962B2 (en) | 2005-12-19 | 2015-08-18 | Sicor, Inc. | Forms of tiotropium bromide and processes for preparation thereof |
US8163913B2 (en) * | 2005-12-19 | 2012-04-24 | Sicor Inc. | Forms of tiotropium bromide and processes for preparation thereof |
EP2201934A1 (fr) | 2008-12-23 | 2010-06-30 | CHIESI FARMACEUTICI S.p.A. | Produits de formule d'aérosol de tiotropium avec stabilité chimique améliorée |
SG181870A1 (en) | 2009-12-23 | 2012-07-30 | Chiesi Farma Spa | Aerosol formulation for copd |
EP2515855B3 (fr) | 2009-12-23 | 2023-05-03 | Chiesi Farmaceutici S.p.A. | Polythérapie pour la COPD |
GB201200525D0 (en) * | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
GB201200504D0 (en) * | 2011-12-19 | 2012-02-22 | Teva Branded Pharmaceutical Prod R & D Inc | An inhaler |
WO2013127738A1 (fr) | 2012-02-28 | 2013-09-06 | Boehringer Ingelheim International Gmbh | Nouvelle formulation de tiotropium contenant un gaz propulseur |
CA2885767A1 (fr) * | 2012-10-23 | 2014-05-01 | Cipla Limited | Composition pharmaceutique |
US20160250197A1 (en) * | 2013-11-22 | 2016-09-01 | Teva Branded Pharmaceutical Products R&D, Inc. | An inhalable medicament |
US10034866B2 (en) | 2014-06-19 | 2018-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament comprising tiotropium |
ES2904823T3 (es) * | 2016-09-19 | 2022-04-06 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende bromuro de tiotropio |
ES2841649T5 (es) * | 2016-09-19 | 2024-04-24 | Mexichem Fluor Sa De Cv | Composición farmacéutica |
CA3037080C (fr) | 2016-09-19 | 2021-05-18 | Mexichem Fluor S.A. De C.V. | Compositions pharmaceutiques stables comprenant de l'indacaterol et du 1,1-difluoroethane (hfa 152a) pour utilisation dans des aerosols-doseurs |
BR112019005168A2 (pt) | 2016-09-19 | 2019-06-11 | Mexichem Fluor Sa De Cv | composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente que sofre ou susceptível de sofrer de um distúrbio respiratório, para melhoria da estabilidade de uma composição farmacêutica e do desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica |
EP3515432B1 (fr) | 2016-09-19 | 2021-08-25 | Mexichem Fluor S.A. de C.V. | Composition pharmaceutique comprenant glycopyrrolate |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100312357B1 (ko) * | 1992-12-09 | 2002-04-24 | 데이비드 이. 프랭크하우저 | 안정화된약제의에어로졸용액제제 |
DE10056104A1 (de) * | 2000-11-13 | 2002-05-23 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols |
-
2003
- 2003-12-04 CA CA002510043A patent/CA2510043A1/fr not_active Abandoned
- 2003-12-04 CN CNA2003801063667A patent/CN1726038A/zh active Pending
- 2003-12-04 JP JP2004559752A patent/JP2006510680A/ja active Pending
- 2003-12-04 KR KR1020057010885A patent/KR20050085650A/ko not_active Application Discontinuation
- 2003-12-04 BR BR0317340-2A patent/BR0317340A/pt not_active Expired - Fee Related
- 2003-12-04 RU RU2005122444/15A patent/RU2005122444A/ru not_active Application Discontinuation
- 2003-12-04 MX MXPA05006383A patent/MXPA05006383A/es not_active Application Discontinuation
- 2003-12-04 EP EP03813106A patent/EP1575588A1/fr not_active Withdrawn
- 2003-12-04 WO PCT/EP2003/013692 patent/WO2004054580A1/fr active Application Filing
- 2003-12-04 PL PL03375868A patent/PL375868A1/xx unknown
- 2003-12-04 AU AU2003303029A patent/AU2003303029A1/en not_active Abandoned
-
2005
- 2005-05-04 ZA ZA200503546A patent/ZA200503546B/xx unknown
- 2005-06-15 IL IL169178A patent/IL169178A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1726038A (zh) | 2006-01-25 |
WO2004054580A1 (fr) | 2004-07-01 |
AU2003303029A1 (en) | 2004-07-09 |
PL375868A1 (en) | 2005-12-12 |
RU2005122444A (ru) | 2007-01-27 |
KR20050085650A (ko) | 2005-08-29 |
ZA200503546B (en) | 2006-10-25 |
BR0317340A (pt) | 2005-11-08 |
JP2006510680A (ja) | 2006-03-30 |
EP1575588A1 (fr) | 2005-09-21 |
MXPA05006383A (es) | 2005-08-29 |
IL169178A0 (en) | 2007-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090175802A1 (en) | Tiotropium containing hfc solution formulations | |
CA2531847C (fr) | Preparations de hfc en solution contenant un anticholinergique | |
CA2510043A1 (fr) | Formulations de solutions aux hfc contenant du tiotropium | |
EP0673240B1 (fr) | Formulations de solutions medicinales aerosol stabilisees | |
US7736627B2 (en) | HFA suspension formulations containing an anticholinergic | |
KR20110096538A (ko) | 약제학적 에어로졸 조성물 | |
EA012369B1 (ru) | Новые соли тиотропия, способ их получения, а также содержащие их лекарственные композиции | |
UA82413C2 (uk) | Спосіб одержання солей тіотропію, солі тіотропію, а також лікарський засіб, який їх містить | |
CA2479640C (fr) | Formulations de hfa en suspensions contenant un anticholinergique | |
JP5147158B2 (ja) | 無水物のhfa懸濁製剤 | |
US7244415B2 (en) | HFA suspension formulations of an anhydrate | |
RU2006136025A (ru) | Ингаляционные композиции |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |